805 related articles for article (PubMed ID: 17427498)
1. [Assessment of postvaccinal response in children past pertussis].
Grzybowska K; Przybyszewski M; Banasik M; Płaneta-Małecka I; Zeman K
Wiad Lek; 2006; 59(11-12):819-22. PubMed ID: 17427498
[TBL] [Abstract][Full Text] [Related]
2. [Immunogenicity and reactogenicity of acellular pertussis vaccines intended for adolescent and adults].
Zawadka M; Lutyńska A
Przegl Epidemiol; 2012; 66(1):99-105. PubMed ID: 22708307
[TBL] [Abstract][Full Text] [Related]
3. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases
Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
[TBL] [Abstract][Full Text] [Related]
4. Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis.
Wilson TR
J Pediatr Health Care; 2006; 20(4):229-37. PubMed ID: 16831630
[TBL] [Abstract][Full Text] [Related]
5. Why do pertussis vaccines fail?
Cherry JD
Pediatrics; 2012 May; 129(5):968-70. PubMed ID: 22529282
[No Abstract] [Full Text] [Related]
6. [Time for booster doses against whooping cough for 10-year-old children].
Carlsson RM; Ekholm L; Gothefors L; Granström M; Trolin I; Tegnell A
Lakartidningen; 2005 Aug 29-Sep 4; 102(35):2394-8. PubMed ID: 16184889
[TBL] [Abstract][Full Text] [Related]
7. [Immunity of children aged 6-8 against pertussis, tetanus and diphtheria].
Slusarczyk J; Dulny G; Nowak K; Krszyna J; Wysokińska T; Fordymacka A; Gzyl A; Janaszek W; Gniadek G
Przegl Epidemiol; 2002; 56(1):39-48. PubMed ID: 12150066
[TBL] [Abstract][Full Text] [Related]
8. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM
Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
Gustafsson L; Hessel L; Storsaeter J; Olin P
Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
[TBL] [Abstract][Full Text] [Related]
11. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.
McIntyre PB; Turnbull FM; Egan AM; Burgess MA; Wolter JM; Schuerman LM
Vaccine; 2004 Dec; 23(3):380-5. PubMed ID: 15530684
[TBL] [Abstract][Full Text] [Related]
12. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.
Hallander HO; Ljungman M; Jahnmatz M; Storsaeter J; Nilsson L; Gustafsson L
APMIS; 2009 Sep; 117(9):660-71. PubMed ID: 19703126
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of pertussis immune responses to tetanus-diphtheria-acellular pertussis vaccine in health care personnel: implications for outbreak control.
Kirkland KB; Talbot EA; Decker MD; Edwards KM
Clin Infect Dis; 2009 Aug; 49(4):584-7. PubMed ID: 19589084
[TBL] [Abstract][Full Text] [Related]
14. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
15. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
Tapiainen T; Cherry JD; Heininger U
Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
[TBL] [Abstract][Full Text] [Related]
16. The present and future control of pertussis.
Cherry JD
Clin Infect Dis; 2010 Sep; 51(6):663-7. PubMed ID: 20704492
[No Abstract] [Full Text] [Related]
17. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.
Knuf M; Zepp F; Meyer C; Grzegowski E; Wolter J; Riffelmann M; Wirsing von König CH
Vaccine; 2006 Mar; 24(12):2043-8. PubMed ID: 16356597
[TBL] [Abstract][Full Text] [Related]
18. [Old problems and new strategies in the fight against pertussis].
Carlino C; Zaratti L; Franco E
Ig Sanita Pubbl; 2013; 69(4):473-80. PubMed ID: 24091847
[TBL] [Abstract][Full Text] [Related]
19. What's wrong with acellular pertussis vaccines?
Wiedermann BL
Clin Ther; 2013 Feb; 35(2):115-8. PubMed ID: 23375491
[No Abstract] [Full Text] [Related]
20. [Pertussis vaccination with acellular vaccines. Tolerance--effectiveness--current vaccination recommendations].
Liese JG; Stojanov S; Belohradsky BH
Fortschr Med; 1997 Aug; 115(24):22-7. PubMed ID: 9410815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
